Characteristics of the study population.
| Characteristics | Total JPsA | Nonoverweight | Overweight | p |
|---|---|---|---|---|
| Patients, n (%) | 320 | 204 (63.8) | 116 (36.3) | |
| Age at symptom onset, yrs, mean ± SD | 8.29 ± 4.65 | 7.74 ± 4.67 | 9.26 ± 4.48 | 0.005 |
| Age at first rheumatologist visit, yrs, mean ± SD | 9.40 ± 4.60 | 8.72 ± 4.65 | 10.59 ± 4.30 | 0.0005 |
| Interval between onset and first assessment, yrs, mean ± SD | 1.03 ± 1.45 | 0.91 ± 1.17 | 1.25 ± 1.82 | NS |
| Sex, n (%) | ||||
| Male | 113 (35.3) | 67 (32.8) | 46 (39.7) | NS |
| Female | 207 (64.7) | 137 (67.2) | 70 (60.3) | |
| Race, n (%) | ||||
| White | 301 (94.1) | 195 (95.6) | 106 (91.4) | NS |
| Other | 19 (5.9) | 9 (4.4) | 10 (8.6) | |
| Ethnicity | ||||
| Hispanic or Latino | 28 (8.8) | 18 (8.8) | 10 (8.6) | NS |
| Not Hispanic or Latino | 292 (91.3) | 186 (91.2) | 106 (91.4) | |
| Family history, n (%) | ||||
| Psoriasis | 103 (32.2) | 70 (34.3) | 33 (28.4) | NS |
| JIA | 10 (3.1) | 5 (2.5) | 5 (4.3) | NS |
| RA | 32 (10.0) | 19 (9.3) | 13 (11.2) | NS |
| Clinical characteristics, n (%) | ||||
| Affected joints | ||||
| < 5 | 140 (44.2) | 92 (45.5) | 48 (41.7) | NS |
| ≥ 5 | 177 (55.8) | 110 (54.5) | 67 (58.3) | |
| Nail pitting | 103 (34.1) | 58 (30.2) | 45 (40.9) | NS |
| Dactylitis | 94 (29.4) | 60 (29.4) | 34 (29.3) | NS |
| Psoriasis | 211 (68.5) | 129 (66.5) | 82 (71.9) | NS |
| Enthesitis | 91 (30.1) | 58 (30.2) | 33 (30.0) | NS |
| SI joint tenderness | 53 (17.5) | 28 (14.7) | 25 (22.5) | NS |
| Uveitis | 35 (11.4) | 22 (11.3) | 13 (11.5) | NS |
| Laboratory values, n (%) | ||||
| IgM RF | 4 (1.3) | 3 (1.5) | 1 (0.9) | NS |
| ANA | ||||
| Negative | 136 (2.5) | 82 (40.2) | 54 (46.6) | NS |
| Not done | 59 (18.4) | 37 (18.1) | 22 (19.0) | |
| Positive | 125 (39.1) | 40 (34.5) | 85 (41.7) | |
| HLA-B27–positive | 22 (10.4) | 13 (9.9) | 9 (11.3) | NS |
| Radiological variables, n (%) | ||||
| Evidence of joint damage | 67 (25.1) | 38 (22.5) | 29 (29.6) | NS |
| Active inflammation of SI joint | 8 (28.6) | 4 (22.2) | 4 (40.0) | NS |
| Outcome measures, mean ± SD | ||||
| HRQOL | 2.17 ± 0.85 | 2.12 ± 0.85 | 2.27 ± 0.83 | NS |
| Parent/subject overall well-being | 2.33 ± 2.22 | 2.15 ± 2.15 | 2.64 ± 2.32 | 0.05 |
| Parent/subject pain score | 2.54 ± 2.65 | 2.37 ± 2.60 | 2.83 ± 2.72 | NS |
| CHAQ | 0.35 ± 0.49 | 0.31 ± 0.48 | 0.42 ± 0.52 | 0.05 |
| PGA | 1.53 ± 1.76 | 1.50 ± 1.83 | 1.59 ± 1.63 | NS |
| ACR functional class, n (%) | ||||
| Class I | 250 (79.9) | 166 (83.4) | 84 (73.7) | NS |
| Class II | 57 (18.2) | 30 (15.1) | 27 (23.7) | |
| Class III | 6 (1.9) | 3 (1.5) | 3 (2.6) | |
| Therapy | ||||
| Nonbiologics, immune modulators, or DMARD, n (%) | 257 (80.3) | 163 (79.9) | 94 (81.0) | NS |
| HCQ | 13 (4.1) | 5 (2.5) | 8 (6.9) | 0.05 |
| LEF | 12 (3.8) | 9 (4.4) | 3 (2.6) | NS |
| MTX | 167 (52.2) | 106 (52.0) | 61 (52.6) | NS |
| SSZ | 27 (8.4) | 20 (9.8) | 7 (6.0) | NS |
| Biologics | 160 (50.0) | 94 (46.1) | 66 (56.9) | NS |
| ADA | 63 (19.7) | 37 (18.1) | 26 (22.4) | NS |
| ETN | 119 (37.2) | 64 (31.4) | 55 (47.4) | 0.004 |
| IFX | 30 (9.4) | 21 (10.3) | 9 (7.8) | NS |
| Glucocorticoids | 167 (52.2) | 101 (49.5) | 66 (56.9) | NS |
| NSAID (daily) | 148 (46.3) | 97 (47.5) | 51 (44.0) | NS |
BMI: body mass index; JPsA: juvenile psoriatic arthritis; JIA: juvenile idiopathic arthritis; RA: rheumatoid arthritis; RF: rheumatoid factor; IgM: immunoglobulin M; ANA: antinuclear antibodies; SI: sacroiliac; HRQOL: health-related quality of life; CHAQ: Childhood Health Assessment Questionnaire; PGA: physician’s global assessment score; ACR: American College of Rheumatology; DMARD: disease-modifying antirheumatic drug; HCQ: hydroxychloroquine; LEF: leflunomide; MTX; methotrexate; SSZ: sulfasalazine; ADA: adalimumab; ETN: etanercept; IFX: infliximab; NSAID: nonsteroidal antiinflammatory drug; NS: nonsignificant.